To enhance service speed and avoid tariff delays, we've opened a US warehouse. All US orders ship directly from our US facility.
| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DC20512 | VHL ligand 1 Featured |
PROTAC-VHL-ligand is a von Hippel–Lindau (VHL) ligand used for the proteolysis targeting chimeras (PROTACs) method, induces target protein degradation..
More description
|
|
| DC8456 | Cardiogenol C (hydrochloride) Featured |
Cardiogenol C is a diaminopyrimidine that induces cardiomyogenesis in mouse embryonic stem cells.
More description
|
|
| DC10847 | CAY10441(RO1138452) Featured |
CAY10441 is a Selective prostacyclin IP receptor antagonist.
More description
|
|
| DC10903 | CAY10465 Featured |
CAY10465 is an analog of resveratrol acting as a potent and selective aryl hydrocarbon receptor agonist, with a Ki of 0.2 nM.
More description
|
|
| DC10579 | CAY 10602 Featured |
CAY10602 is a SIRT1 activator.
More description
|
|
| DC4160 | CB-03-01 Featured |
CB-03-01 is a steroidal ester, androgen antagonist derived from 11-deoxycortisone, which tightly mimics the profile of an ideal anti-androgen for topical use.
More description
|
|
| DC10449 | CB7921220 Featured |
CB7921220 is an inhibitor of Adenylyl Cyclase isoform-1 (AC1) and isoform-6 (AC6).
More description
|
|
| DC8497 | CC-223 Featured |
CC-223 is a potent mTOR kinase inhibitor (IC50=16 nM), with >150-fold sensitivity over the related lipid kinase PI3Kα (IC50=4 μM).
More description
|
|
| DC7096 | CC-401 Featured |
CC-401 is a second generation ATP-competitive anthrapyrazolone c-Jun N terminal kinase (JNK) inhibitor with potential antineoplastic activity.
More description
|
|
| DC11302 | CCG215022 Featured |
CCG215022 is a G protein-coupled receptor kinases (GRKs) inhibitor with IC50s of 0.15±0.07 μM, 0.38±0.06 μM and 3.9±1 μM for GRK2, GRK5 and GRK1, respectively.
More description
|
|
| DC10005 | CCT196969 Featured |
CCT196969 is a novel orally available, pan-RAF inhibitor with anti-SRC activity.
More description
|
|
| DC8324 | CCT244747 Featured |
CCT244747 represents the first structural disclosure of a highly selective, orally active CHK1 inhibitor and warrants further evaluation alone or combined with genotoxic anticancer therapies.
More description
|
|
| DC10909 | BN82002 Featured |
CDC25 Phosphatase Inhibitor I, BN82002, is a cell-permeable ortho-hydroxybenzylamino compound that has been reported to display antitumor properties.
More description
|
|
| DC12026 | CDDO-2P-Imidazolide Featured |
CDDO-2P-Im is a new analogue of CDDO-Imidazolid,showing better bioactive than CDDO-Imidazolid.
More description
|
|
| DC12027 | CDDO-3P-Imidazolide Featured |
CDDO-3P-Im is a new analogue of CDDO-Imidazolid,showing better bioactive than CDDO-Imidazolid.
More description
|
|
| DC12025 | CDDO imidazolide Featured |
CDDO-imidazolide is a potent inducer of heme oxygenase-1 and Nrf2/ARE signaling,with potent antiproliferative, differentiating, and anti-inflammatory activities.
More description
|
|
| DC9277 | C-DIM12 Featured |
C-DIM12 is a novel synthetic activator of Nurr1.
More description
|
|
| DC20334 | CDK2 inhibitor 73 Featured |
CDK2 inhibitor 73 is a potent, selective CDK2 inhibitor with IC50 of 44 nM for CDK2/cyclin A, displays 2,000-fold selectivity over CDK1/cyclin B (IC50=86 uM)..
More description
|
|
| DC40786 | (S,R,S)-AHPC-C6-NH2 hydrochloride Featured |
(S,R,S)-AHPC-C6-NH2 hydrochloride (VH032-C6-NH2 hydrochloride) is a synthesized?E3 ligase ligand-linker conjugate?that incorporates the VH032 based VHL ligand and a linker used for AKT PROTAC degrader. (S,R,S)-AHPC-C6-NH2 hydrochloride is XF038-161A, example 6, extracted from patent WO2019173516A1.
More description
|
|
| DC48426 | Rafutrombopag |
Rafutrombopag is a thrombopoietin (TPO) agonist extracted from patent CN113929668 A.
More description
|
|
| DC48425 | TGFβR-IN-1 |
TGFβR-IN-1 is a long-acting tumor-activated prodrug of a TGFβR inhibitor.
More description
|
|
| DC48423 | Boc-NH-PEG11-OH |
Boc-NH-PEG11-OH is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.
More description
|
|
| DC48422 | 6-Bnz-cAMP sodium salt |
6-Bnz-cAMP sodium salt is a cell-permeable cAMP analog. 6-Bnz-cAMP selectively activates cAMP-dependent PKA but not Epac signaling pathways.
More description
|
|
| DC48421 | SHP2 protein degrader-1 |
SHP2 protein degrader-1 is a potent allosteric inhibitor of SHP2. SHP2 protein degrader-1 induces SHP2 degradation and cell apoptosis. SHP2 protein degrader-1 has the potential for the treatment of SHP2 related diseases.
More description
|
|
| DC48420 | Orexin B, rat, mouse TFA |
Orexin B, rat, mouse (Rat orexin B) TFA is an endogenous orexin receptor agonist. Orexin B, rat, mouse TFA binds and activates two closely related orphan G protein-coupled receptors OX1-R and OX2-R. Orexin B, rat, mouse TFA stimulates food intake and energy expenditure and plays a significant role in sleep-wakefulness regulation.
More description
|
|
| DC48419 | MA242 free base |
MA242 free base is a specific dual inhibitor of MDM2 and NFAT1. MA242 free base directly binds both MDM2 and NFAT1 with high affinity, induces their protein degradation, and inhibits NFAT1-mediated transcription of MDM2. MA242 free base induces apoptosis in pancreatic cancer cell lines regardless of p53 status.
More description
|
|
| DC48417 | IL-17A inhibitor 2 |
IL-17A inhibitor 2 is an IL-17A inhibitor for treating psoriasis, rheumatoid arthritis, and multiple sclerosis.
More description
|
|
| DC48416 | Brecanavir |
Brecanavir (GW640385) is a novel, potent HIV protease inhibitor.
More description
|
|
| DC48415 | Pirmitegravir |
Pirmitegravir is a potent and first-in-class inhibitor of allosteric integrase (ALLINI) that targets LEDGF/p75 binding site. Pirmitegravir displays picomolar IC50 in human PBMCs with a >24,000 therapeutic index against HIV-1. Pirmitegravir harbors outstanding anti-virus and safety properties.
More description
|
|
| DC48414 | EZH2-IN-6 |
EZH2-IN-6 is an EZH2 inhibitor with enhanced antitumor activity.
More description
|
|